Prevention and treatment a major focus of FDA’s food allergy regulatory push

By Scarlett Salem, MS, MPH

The FDA is expanding its focus on food allergies beyond labeling and allergen thresholds, with agency leadership increasingly emphasizing prevention strategies and new therapeutic approaches. Recent public meetings and expert panels convened by the agency highlight growing scientific consensus around early allergen introduction and the potential role of immunotherapies in managing food allergies.

At the same time, discussions exposed key regulatory tensions — particularly around how prevention-related messaging can appear on food labels without triggering drug claims, as well as the clinical and reimbursement challenges involved in scaling treatment.

This AgencyIQ analysis examines how evolving science, regulatory constraints and policy priorities are shaping the FDA’s broader food allergy agenda.

Fill out the form to read the full analysis.